Artículos de revistas sobre el tema "Benralizumab"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Benralizumab".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Antoniu, S. A. "Benralizumab". Drugs of the Future 39, n.º 7 (2014): 463. http://dx.doi.org/10.1358/dof.2014.039.07.2156125.
Texto completoZhuravleva, M. V., S. N. Avdeev, Yu V. Gagarina y T. V. Marin. "Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings". FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15, n.º 2 (27 de julio de 2022): 175–86. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2022.143.
Texto completoBourdin, Arnaud, Don Husereau, Nicolas Molinari, Sarowar Golam, Mohd Kashif Siddiqui, Leandro Lindner y Xiao Xu. "Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review". European Respiratory Journal 52, n.º 5 (11 de octubre de 2018): 1801393. http://dx.doi.org/10.1183/13993003.01393-2018.
Texto completoAndo, Koichi, Akihiko Tanaka y Hironori Sagara. "Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review". International Journal of Molecular Sciences 21, n.º 3 (30 de enero de 2020): 889. http://dx.doi.org/10.3390/ijms21030889.
Texto completoBleecker, Eugene R., Michael E. Wechsler, J. Mark FitzGerald, Andrew Menzies-Gow, Yanping Wu, Ian Hirsch, Mitchell Goldman, Paul Newbold y James G. Zangrilli. "Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma". European Respiratory Journal 52, n.º 4 (23 de agosto de 2018): 1800936. http://dx.doi.org/10.1183/13993003.00936-2018.
Texto completoYamada, Hideyasu, Masayuki Nakajima, Masashi Matsuyama, Yuko Morishima, Naoki Arai, Norihito Hida, Taisuke Nakaizumi et al. "Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma". PLOS ONE 16, n.º 3 (11 de marzo de 2021): e0248305. http://dx.doi.org/10.1371/journal.pone.0248305.
Texto completoTitova, Olga N., Natalia A. Kuzubova, Daria B. Sklyarova y Maria A. Petrova. "The effectiveness of benralizumab in the treatment of the eosinophilic phenotype of severe asthma in real clinical practice". PULMONOLOGIYA 31, n.º 5 (20 de octubre de 2021): 628–34. http://dx.doi.org/10.18093/0869-0189-2021-31-5-628-634.
Texto completoTsurumaki, Matsuyama, Ezawa, Koga, Yatomi, Aoki-Saito, Chikamatsu y Hisada. "Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis". Medicina 55, n.º 7 (3 de julio de 2019): 336. http://dx.doi.org/10.3390/medicina55070336.
Texto completoNedogoda, Sergey Vladimirovich, Alla Sergeevna Salasyuk, Irina Nikolaevna Barykina, Victoria Olegovna Smirnova y Maksim Yurevich Frolov. "Сost of the Biologacal Therapy for Severe Brochcial Asthma Treatment at Inpatient and Day Care Setting". Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор), n.º 1 (39) (1 de mayo de 2020): 61–69. http://dx.doi.org/10.31556/2219-0678.2020.39.1.061-069.
Texto completoMarkham, A. "Benralizumab: First Global Approval". Drugs 78, n.º 4 (20 de febrero de 2018): 505–11. http://dx.doi.org/10.1007/s40265-018-0876-8.
Texto completoLombardo, Nicola, Corrado Pelaia, Marco Ciriolo, Marcello Della Corte, Giovanna Piazzetta, Nadia Lobello, Pasquale Viola y Girolamo Pelaia. "Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma". International Journal of Immunopathology and Pharmacology 34 (enero de 2020): 205873842095085. http://dx.doi.org/10.1177/2058738420950851.
Texto completoLászló, Nimród, Hédy Katalin Sárközy, Cristina Alexandra Man, Edith Simona Ianoși, Botond Mátyás, Bianca Emilia Ciurba, Corina Mărginean y Gabriela Jimborean. "The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)". Journal of Interdisciplinary Medicine 6, n.º 3 (1 de septiembre de 2021): 157–61. http://dx.doi.org/10.2478/jim-2021-0030.
Texto completoPintea, Irena, Ioana Adriana Muntean, Carmen Teodora Dobrican, Nicolae Miron y Diana Deleanu. "Off-Label Benralizumab in Severe Non-Necrotizing Eosinophilic Vasculitis following Critical COVID-19 Disease and in DRESS". Journal of Clinical Medicine 11, n.º 22 (9 de noviembre de 2022): 6642. http://dx.doi.org/10.3390/jcm11226642.
Texto completoPelaia, Corrado, Claudia Crimi, Santi Nolasco, Giovanna Elisiana Carpagnano, Raffaele Brancaccio, Enrico Buonamico, Raffaele Campisi et al. "Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy". Biomedicines 9, n.º 12 (3 de diciembre de 2021): 1822. http://dx.doi.org/10.3390/biomedicines9121822.
Texto completoCañas, José A., Marcela Valverde-Monge, José M. Rodrigo-Muñoz, Beatriz Sastre, Marta Gil-Martínez, Raquel García-Latorre, Manuel J. Rial et al. "Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma". Journal of Personalized Medicine 11, n.º 2 (28 de enero de 2021): 76. http://dx.doi.org/10.3390/jpm11020076.
Texto completoVitale, Carolina, Angelantonio Maglio, Corrado Pelaia, Maria D’Amato, Luigi Ciampo, Giulia Pelaia, Antonio Molino y Alessandro Vatrella. "Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting". Journal of Clinical Medicine 12, n.º 3 (27 de enero de 2023): 985. http://dx.doi.org/10.3390/jcm12030985.
Texto completoBernstein, Jonathan A., Umesh Singh, Marepalli B. Rao, Karen Berendts, Xiang Zhang y Diya Mutasim. "Benralizumab for Chronic Spontaneous Urticaria". New England Journal of Medicine 383, n.º 14 (1 de octubre de 2020): 1389–91. http://dx.doi.org/10.1056/nejmc2016395.
Texto completoCooke, W. Donald y Abigail Tarr Cooke. "Eosinophilic cystitis treatment with benralizumab". Journal of Allergy and Clinical Immunology 145, n.º 2 (febrero de 2020): AB67. http://dx.doi.org/10.1016/j.jaci.2019.12.734.
Texto completoMurray, Toby, Ben Haagsma y Andrew Chetwood. "Non-infective cystitis secondary to benralizumab immunotherapy". BMJ Case Reports 15, n.º 1 (enero de 2022): e244733. http://dx.doi.org/10.1136/bcr-2021-244733.
Texto completoSereda, V. P., D. A. Svirido, M. V. Komarov, Zhanna A. Mironova y M. A. Nyoma. "Experience of using benralizumab in the treatment of patients with severe asthma in the clinical practice of pulmonologists in Saint-Petersburg". PULMONOLOGIYA 32, n.º 5 (21 de septiembre de 2022): 670–77. http://dx.doi.org/10.18093/0869-0189-2022-32-5-670-677.
Texto completoVantaggiato, Lorenza, Paolo Cameli, Laura Bergantini, Miriana d’Alessandro, Enxhi Shaba, Alfonso Carleo, Fabrizio Di Giuseppe et al. "Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment". Biomedicines 10, n.º 4 (24 de marzo de 2022): 761. http://dx.doi.org/10.3390/biomedicines10040761.
Texto completoJauhiainen, Alexandra, Lieke E. J. M. Scheepers, Anne L. Fuhlbrigge, Tim Harrison, James Zangrilli, Esther Garcia Gil, Per Gustafson, Malin Fagerås y Carla A. Da Silva. "Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations". ERJ Open Research 6, n.º 4 (octubre de 2020): 00246–2020. http://dx.doi.org/10.1183/23120541.00246-2020.
Texto completoLacouture, Mario E., Alexander Pan, George Dranitsaris, Ucalene Harris, Sarat Chandarlapaty, Chau T. Dang, Devika Gajria et al. "Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 12100. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.12100.
Texto completoLacouture, Mario E., Alexander Pan, George Dranitsaris, Ucalene Harris, Sarat Chandarlapaty, Chau T. Dang, Devika Gajria et al. "Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 12100. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.12100.
Texto completoKrysanov, I. S., V. S. Krysanova y V. Yu Ermakova. "Th e clinical-economic analysis of Dupilumab in severe asthma". Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice, n.º 5 (14 de febrero de 2021): 15–26. http://dx.doi.org/10.37489/2588-0519-2020-5-15-26.
Texto completoMiralles-López, Juan Carlos, Rubén Andújar-Espinosa, Francisco Javier Bravo-Gutiérrez, Manuel Castilla-Martínez, Isabel Flores-Martín, María Loreto Alemany-Francés, Manuel José Pajarón-Fernández et al. "Analysis of response of severe eosinophilic asthmatic patients to benralizumab". Allergologia et Immunopathologia 50, n.º 6 (1 de noviembre de 2022): 163–68. http://dx.doi.org/10.15586/aei.v50i6.704.
Texto completoShimizu, Hideyasu, Masamichi Hayashi, Hisayuki Kato, Mitsuru Nakagawa, Kazuyoshi Imaizumi y Mitsushi Okazawa. "IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma". International Journal of Molecular Sciences 22, n.º 20 (18 de octubre de 2021): 11209. http://dx.doi.org/10.3390/ijms222011209.
Texto completoLaorden, Daniel, David Romero y Javier Domínguez-Ortega. "Benralizumab in eosinophilic granulomatosis with polyangiitis". Medicina Clínica (English Edition) 158, n.º 9 (mayo de 2022): 441–42. http://dx.doi.org/10.1016/j.medcle.2021.07.018.
Texto completoSugino, Keishi, Hirotaka Ono, Akira Hebisawa y Eiyasu Tsuboi. "Eosinophilic bronchiolitis successfully treated with benralizumab". BMJ Case Reports 14, n.º 10 (octubre de 2021): e246058. http://dx.doi.org/10.1136/bcr-2021-246058.
Texto completoMatera, M. G., P. Rogliani, L. Calzetta, G. W. Canonica y M. Cazzola. "Benralizumab for the treatment of asthma". Drugs of Today 53, n.º 12 (2017): 633. http://dx.doi.org/10.1358/dot.2017.53.12.2736670.
Texto completoKuang, Fei Li, Fanny Legrand, Michelle Makiya, JeanAnne Ware, Lauren Wetzler, Thomas Brown, Tamika Magee et al. "Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome". New England Journal of Medicine 380, n.º 14 (4 de abril de 2019): 1336–46. http://dx.doi.org/10.1056/nejmoa1812185.
Texto completoSaco, Tara Vinyette, Amber N. Pepper y Richard F. Lockey. "Benralizumab for the treatment of asthma". Expert Review of Clinical Immunology 13, n.º 5 (19 de abril de 2017): 405–13. http://dx.doi.org/10.1080/1744666x.2017.1316194.
Texto completoHussar, Daniel A. y Justin George. "Erenumab-aooe, Benralizumab, and Tezacaftor/ivacaftor". Journal of the American Pharmacists Association 58, n.º 5 (septiembre de 2018): 579–82. http://dx.doi.org/10.1016/j.japh.2018.07.006.
Texto completoGriscti Soler, Daniel, Alessandra Bennici, Silvia Brunetto, Sebastiano Gangemi y Luisa Ricciardi. "Benralizumab in the management of rare primary eosinophilic lung diseases". Allergy and Asthma Proceedings 43, n.º 6 (1 de noviembre de 2022): 494–500. http://dx.doi.org/10.2500/aap.2022.43.220056.
Texto completoWechsler, M., P. A. Merkel, S. Necander, L. Börjesson Sjö, E. A. Duncan, N. Makulova, G. D’angelo et al. "AB0619 Rationale and Design of the 52-week, Randomized, Phase 3, Head-to-Head MANDARA Study to Evaluate the Efficacy and Safety of Benralizumab, a Humanized, Anti-interleukin–5 Receptor α Monoclonal Antibody in Refractory or Relapsing Eosinophilic Granulomatosis with Polyangiitis". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de mayo de 2022): 1435.2–1436. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2075.
Texto completoIgnatova, G. L., V. N. Antonov, E. V. Blinova, I. V. Grebneva y E. V. Sheklanova. "New therapy options for patients with eosinophilic type of severe bronchial asthma". Medical Council, n.º 21 (28 de enero de 2020): 111–16. http://dx.doi.org/10.21518/2079-701x-2019-21-111-116.
Texto completoLeuppi, Jörg D., Peter Schmid-Grendelmeier, Thomas Rothe, Christophe von Garnier, Hans-Uwe Simon, Claudio Schuoler, Gunther Pendl y Markus Solèr. "Benralizumab: Der IL-5-Rezeptor als Ziel bei schwerem eosinophilem Asthma". Praxis 108, n.º 7 (mayo de 2019): 469–76. http://dx.doi.org/10.1024/1661-8157/a003222.
Texto completoLeuppi, Jörg D., Peter Schmid-Grendelmeier, Thomas Rothe, Christophe von Garnier, Hans-Uwe Simon, Claudio Schuoler, Gunther Pendl y Markus Solèr. "Benralizumab: Cibler le récepteur de l’IL-5 dans l’asthme sévère éosinophile". Praxis 108, n.º 7 (mayo de 2019): 1–8. http://dx.doi.org/10.1024/1661-8157/a003250.
Texto completoMenzella, Francesco, Mirco Lusuardi, Carla Galeone, Nicola Facciolongo y Luigi Zucchi. "The clinical profile of benralizumab in the management of severe eosinophilic asthma". Therapeutic Advances in Respiratory Disease 10, n.º 6 (19 de septiembre de 2016): 534–48. http://dx.doi.org/10.1177/1753465816667659.
Texto completoNolasco, Santi, Raffaele Campisi, Rossella Intravaia, Morena Porto, Corrado Pelaia, Nunzio Crimi y Claudia Crimi. "Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use". F1000Research 9 (23 de junio de 2020): 637. http://dx.doi.org/10.12688/f1000research.24603.1.
Texto completoNolasco, Santi, Raffaele Campisi, Rossella Intravaia, Morena Porto, Corrado Pelaia, Nunzio Crimi y Claudia Crimi. "Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use". F1000Research 9 (23 de julio de 2020): 637. http://dx.doi.org/10.12688/f1000research.24603.2.
Texto completoMorimoto, Hiroki, Kensuke Fukuchi, Yasuaki Ogura, Masaki Ohtsuka y Yoshiki Tokura. "Development of lichen planus following benralizumab treatment". European Journal of Dermatology 31, n.º 2 (abril de 2021): 261–62. http://dx.doi.org/10.1684/ejd.2021.3995.
Texto completoEngler, D. "M271 SEVERE EOSINOPHILIC CYSTITIS CONTROLLED WITH BENRALIZUMAB". Annals of Allergy, Asthma & Immunology 127, n.º 5 (noviembre de 2021): S122. http://dx.doi.org/10.1016/j.anai.2021.08.388.
Texto completoCushen, Breda y Andrew Menzies-Gow. "Benralizumab: an updated treatment of eosinophilic asthma". Expert Review of Respiratory Medicine 14, n.º 5 (17 de marzo de 2020): 435–44. http://dx.doi.org/10.1080/17476348.2020.1739526.
Texto completoMishra, Ajay Kumar, Kamal Kant Sahu y Atem James. "Disseminated herpes zoster following treatment with benralizumab". Clinical Respiratory Journal 13, n.º 3 (17 de febrero de 2019): 189–91. http://dx.doi.org/10.1111/crj.12998.
Texto completoCriner, Gerard J., Bartolome R. Celli, Christopher E. Brightling, Alvar Agusti, Alberto Papi, Dave Singh, Don D. Sin et al. "Benralizumab for the Prevention of COPD Exacerbations". New England Journal of Medicine 381, n.º 11 (12 de septiembre de 2019): 1023–34. http://dx.doi.org/10.1056/nejmoa1905248.
Texto completoFabbri, Leonardo M. "Benralizumab: for asthma, not yet for COPD". Lancet Respiratory Medicine 2, n.º 11 (noviembre de 2014): 862–63. http://dx.doi.org/10.1016/s2213-2600(14)70225-5.
Texto completoDagher, Rania, Varsha Kumar, Alan M. Copenhaver, Sandra Gallagher, Mahboobe Ghaedi, Jonathan Boyd, Paul Newbold, Alison A. Humbles y Roland Kolbeck. "Novel mechanisms of action contributing to Benralizumab's potent anti-eosinophilic activity". European Respiratory Journal, 21 de julio de 2021, 2004306. http://dx.doi.org/10.1183/13993003.04306-2020.
Texto completo"Benralizumab". Reactions Weekly 1914, n.º 1 (julio de 2022): 126. http://dx.doi.org/10.1007/s40278-022-18712-0.
Texto completo"Benralizumab". Reactions Weekly 1895, n.º 1 (febrero de 2022): 95. http://dx.doi.org/10.1007/s40278-022-10520-1.
Texto completo